Healthtech Startup Avammune Therapeutics Raises $12 Million in Series A Funding
Avammune Therapeutics, a biopharmaceutical startup founded in 2020, has successfully raised $12 million (INR 100 Cr) as part of its Series A funding round. The funding was led by Capital 2B, with participation from Shastra VC and Kotak Alternate Asset Managers’ Life Sciences Fund I.
The company plans to utilize the fresh funds to enhance its intellectual property (IP) portfolio and support the clinical development of its lead candidate, AVA-NP-695. Avammune Therapeutics is focused on discovering small molecule medicines, aiming to address various health-related issues.
The funding round’s success is a significant milestone for Avammune Therapeutics as it continues to work on its innovative biopharmaceutical projects. With the support of its investors, the company is poised to make notable advancements in the healthtech sector.
Source: INC42
